In November 2004, the FDA issued a final rule requiring HCT/P establishments to operate in accordance with Current Good Tissue Practice (CGTP) for the collection, donor screening, donor testing, processing, storage, labeling, packaging and distribution of HCT/Ps to prevent the introduction, transmission and spread of communicable diseases. The core CGTP requirements cover facilities, environmental controls, equipment, supplies and reagents, recovery, processing and processing controls, labeling controls, storage, and distribution (including receipt and predistribution shipment). The regulations for CGTPs are found in 21 CFR 1271 Subpart D; FDA recommendations for compliance with the regulations also are available.
REGULATORY UPDATE: FDA Releases HCT/P Guidance Documents Related to Donor Eligibility
January 07, 2025
FDA Approves First MSC Therapy to Treat GvHD
January 02, 2025
BioBridge Global Launches BBG Advanced Therapies Subsidiary
January 02, 2025